Support for establishing the Therapy Acceleration Laboratory in Oxford to assess clinical trial samples (back translation)

支持在牛津建立治疗加速实验室以评估临床试验样本（反向翻译）

• 批准号: MC_PC_20043
• 负责人: Colin Baigent
• 金额: $ 9.94万
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Intramural
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MC_PC_20043
• 关键词: Support; establishing; Therapy; Acceleration; Laboratory

The Therapy Acceleration Laboratory would: a) Set world-leading standards in quality and impact to study samples, using specialist genetic, immunological, phenotypic and pathological assays, from clinical trials to accelerate therapy development, including supporting registrational trials in partnership with academics, the NHS and industry. b) Enable discovery and application that open new areas of biology with mechanistic studies developed using state-of-the-art technologies and methods.c) Utilise strengths and capability across the UK, and the international biomedical landscape, to attract the most innovative clinical trials with the potential to rapidly transform human health.Of note, there are already three academically sponsored Phase III registrational trials in advanced negotiation due to start between October and December 2021 that would be supported by the TAL. The beneficiaries: would be patients, the three partner MRC Units, the NHS, other academic units throughout the UK, the NHS and industry.

治疗加速实验室将：a)在研究样本的质量和影响方面设定世界领先的标准，使用来自临床试验的专家基因、免疫学、表型和病理分析来加速治疗开发，包括与学术界、NHS和工业界合作支持注册试验。b)通过使用最先进的技术和方法进行机制研究，使发现和应用能够开辟生物学的新领域。c)利用英国和国际生物医学领域的优势和能力，吸引最具创新性的临床试验，这些试验有可能迅速改变人类健康。值得注意的是，已经有三个学术资助的III期注册试验正在进行高级谈判，将于2021年10月至12月开始，这些试验将得到TAL的支持。受益者：将是患者、三个MRC合作单位、NHS、英国各地的其他学术单位、NHS和行业。